SA PRO
Free Account
BioMarin Pharmaceutical Inc.BMRNNASDAQ
LOADING
|||
Switch Symbol:
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts lean bullish — 74% recommend buying.

Consensus Rating
Buy
27 analysts·High coverage
74%
Rating Distribution
Strong Buy
00%
Buy
2074%
Hold
726%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Jan 20, 2026Canaccord Genuity
BioMarin upgraded to Buy from Hold at Canaccord
Target:$98.00
+79.5%from $54.59
Dec 23, 2025Truist Financial
BioMarin price target raised to $100 from $80 at Truist
Target:$100.00
+68.7%from $59.28
Dec 22, 2025H.C. Wainwright
BioMarin price target raised to $60 from $55 at H.C. Wainwright
Target:$60.00
-1.9%from $61.15
Dec 3, 2025Leerink Partners
BioMarin downgraded to Market Perform from Outperform at Leerink
Target:$60.00
+11.3%from $53.89
Nov 3, 2025Tudor Pickering
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered at Bernstein Amid 'Tough NT Setup'
Target:$88.00
+64.3%from $53.57
Nov 3, 2025Bernstein
BioMarin price target lowered to $88 from $95 at Bernstein
Target:$88.00
+64.3%from $53.57
Oct 28, 2025RBC Capital
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $66 at RBC Capital
Target:$66.00
+21.7%from $54.25
Oct 28, 2025Stifel Nicolaus
BioMarin price target lowered to $73 from $91 at Stifel
Target:$73.00
+32.8%from $54.97
Oct 28, 2025Truist Financial
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered at Truist; 'Competitive Pressures Mounting'
Target:$80.00
+46.8%from $54.48
Oct 28, 2025Morgan Stanley
BioMarin price target lowered to $98 from $104 at Morgan Stanley
Target:$98.00
+78.1%from $55.04
Oct 28, 2025H.C. Wainwright
BioMarin price target lowered to $55 from $60 at H.C. Wainwright
Target:$55.00
-0.4%from $55.20
Oct 28, 2025Wells Fargo
BioMarin price target lowered to $70 from $90 at Wells Fargo
Target:$70.00
+27.1%from $55.06
Oct 28, 2025Barclays
BioMarin price target lowered to $80 from $86 at Barclays
Target:$80.00
+51.9%from $52.67
Aug 5, 2025UBS
BioMarin price target raised to $114 from $113 at UBS
Target:$114.00
+84.1%from $61.93
Jul 15, 2025Wolfe Research
Wolfe Research Reiterates Outperform Rating on BioMarin Pharmaceutical Inc. (BMRN)
Target:$95.00
+63.1%from $58.23
Oct 30, 2024Cantor Fitzgerald
BioMarin price target lowered to $90 from $110 at Cantor Fitzgerald
Target:$90.00
+34.3%from $67.00
Oct 30, 2024Robert W. Baird
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $65 at Baird
Target:$65.00
-7.0%from $69.91
Oct 30, 2024Citigroup
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $81 at Citi
Target:$81.00
+15.9%from $69.91
Oct 10, 2024Raymond James
BioMarin reinstated with an Outperform at Raymond James
Target:$79.00
+13.5%from $69.59
Oct 4, 2024Barclays
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $86 at Barclays
Target:$86.00
+23.7%from $69.51
Sep 18, 2024Citigroup
Citi Reiterates Neutral Rating on BioMarin Pharmaceutical Inc. (BMRN)
Target:$93.00
+30.7%from $71.14
Sep 17, 2024Scotiabank
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $78 at Scotiabank
Target:$78.00
+9.5%from $71.21
Sep 17, 2024Truist Financial
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $90 at Truist Securities
Target:$90.00
+26.4%from $71.20
Sep 17, 2024Bernstein
BioMarin price target lowered to $90 from $116 at Bernstein
Target:$90.00
+28.8%from $69.86
Sep 17, 2024BMO Capital
BMO Capital Reiterates BioMarin (BMRN) at Outperform: unique opportunity to buy the dip and can attract M&A interest
Target:$115.00
+61.7%from $71.13

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance